Clinical trials: Docetaxel, completed
Bone Metastases, Castration-Resistant Prostate Cancer
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and…
- Trial name
- NCT01106352
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
- Where
- 7 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Bayer
Breast Cancer, Breast Cancer Female
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-expressed in aggressive breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer
- Trial name
- NCT03387553
- Testing
- Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given…
- Trial name
- NCT00002707
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 145 sites in United States, Canada
- Volunteers
- 2,411 people
- Sponsor
- NSABP Foundation Inc
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
CCND1 Gene Amplification, CCND2 Gene Amplification
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This phase II/III trial studies how well palbociclib works in treating cell cycle gene alteration positive patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification
- Trial name
- NCT02785939
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Palbociclib
- Where
- 1,065 sites in United States
- Volunteers
- 53 people
- Sponsor
- SWOG Cancer Research Network
Non-Small Cell Lung Cancer
Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
This is a clinical research study to evaluate if chemotherapy in the experimental arm (E) results in a better outcome compared to patients in the standard of care arm (C).
- Trial name
- NCT00499109
- Testing
- Docetaxel, Vinorelbine, Carboplatin
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 275 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil.
- Trial name
- NCT00515411
- Testing
- Docetaxel, Leucovorin, Fluorouracil, Cisplatin, Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen, Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab
- Where
- 15 sites in United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell…
- Trial name
- NCT00139711
- Testing
- Irinotecan, Docetaxel
- Where
- 15 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer
- Trial name
- NCT04676607
- Testing
- SHR7390
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment.
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02965378
- Testing
- Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
- Where
- 1,084 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Non-small-cell Lung Cancer
Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)
Randomized Study of Customized Adjuvant Chemotherapy based on BRCA1 mRNA Levels in Completely Resected stages II-IIIA Non-Small-Cell Lung Cancer Patients.
- Trial name
- GECP-SCAT (NCT00478699)
- Testing
- Docetaxel/Cisplatin control, Docetaxel, Gemcitabine/Cisplatin
- Where
- 47 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Spanish Lung Cancer Group
Ovarian Cancer
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis…
- Trial name
- TEACO (NCT00296816)
- Testing
- Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer
This Phase II study is to determine the efficacy of split-course irradiation with concurrent chemotherapy in locally advanced none-small cell lung cancer patients.
- Trial name
- NCT02573506
- Testing
- split-course radiotherapy, Concurrent chemotherapy
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Sun Yat-sen University
Cholangiocarcinoma Cancer, Gallbladder Cancer
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.
- Conditions
- Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
- Trial name
- NCT00660699
- Testing
- Gemcitabine, Docetaxel, Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Neutropenia
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This study was a phase Ib study of the safety and pharmacokinetics/pharmacodynamics of F-627 once per cycle as prophylaxis therapy to chemotherapy in women with breast cancer.
- Trial name
- NCT02522234
- Testing
- F-627 240 μg/kg, F-627 320 μg/kg
- Where
- China
- Volunteers
- 15 people
- Sponsor
- EVIVE Biotechnology
Breast Cancer
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB] and a non anthracycline-based regimen…
- Trial name
- NeoTOP (NCT02339532)
- Testing
- FEC100, Docetaxel, Trastuzumab
- Where
- 12 sites in France
- Volunteers
- 86 people
- Sponsor
- UNICANCER
Prostatic Neoplasms
Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer
Prostate cancer is the second leading cause of mortality in men, representing 10 deaths about of 100 cancers (INVS 2009). Treatment for metastatic prostate cancer, when becoming resistant to hormone-treatment, is mostly resumed…
- Trial name
- TAXOMET (NCT01796028)
- Testing
- METFORMIN, TAXOTERE®
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Antoine Lacassagne
Carcinoma, Non-Small-Cell Lung
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients…
- Trial name
- CONTACT-01 (NCT04471428)
- Testing
- Cabozantinib, Atezolizumab, Docetaxel
- Where
- 92 sites in United States, Australia and 13 more
- Volunteers
- 366 people
- Sponsor
- Hoffmann-La Roche
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
- Trial name
- NCT03248570
- Testing
- Pembrolizumab, Chemotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Stomach Neoplasm
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
Phase II: Primary objective: to select one of the 2 test arms (docetaxel with cisplatin, docetaxel with cisplatin and 5-FU), based primarily on complete responses, to advance to a phase III survival comparison against the CDDP +…
- Trial name
- NCT00290966
- Testing
- XRP6976
- Volunteers
- 610 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.